Pasithea Therapeutics Corp. Warrants
Compare this stock
KTTAW Stock Report Card
$
13%
Performance
Score:
10/100
KTTAW returned -86.00% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Profit
Score:
16/100
Out of the last 12 quarters, KTTAW has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
Score:
10/100
KTTAW has had a lower than average amount of volatility over the last 12 months giving it a score of 10 of 100.
Pasithea Therapeutics Corp. Warrants Summary
Nasdaq / KTTAW
Healthcare
Biotechnology
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
KTTAW scored poorly on our reportcard. Here are some similar companies and how they performed.
